ALVO OAKTREE ACQUISITION CORP II

Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida

Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in Barclays 27th Annual Global Healthcare Conference, which will be held in Miami, Florida on March 11-13, 2025. Robert Wessman, founder, chairman and CEO and members of the management team will host one-on-one meetings. Alvotech will also be participating in a fireside chat on Wednesday, March 12, 2025, at 9:30-9:55 am EDT (13:30-13:55 GMT).

An audio webcast of the fireside chat will also be available to investors and the general public and can be accessed in the of Alvotech’s . After the event, a recording will also be available for 90 days.

About Alvotech

Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech has launched two biosimilars. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit

Please visit our , and our or follow us on social media on , , , and .

ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS

Benedikt Stefansson, VP



EN
07/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OAKTREE ACQUISITION CORP II

 PRESS RELEASE

Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirm...

Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the acquisition of Xbrane Biopharma AB’s (“Xbrane”) R&D operations and a biosimilar candidate (the “Acquisition”), further expanding Alvotech’s development capabilities, and establishing a footprint in the Swedish life science sector. The Acquisition includes Xbrane’s R&D operations based ...

 PRESS RELEASE

Alvotech kaupir þróunarstarfsemi líftæknifyrirtækisins Xbrane í Svíþjó...

Alvotech kaupir þróunarstarfsemi líftæknifyrirtækisins Xbrane í Svíþjóð Alvotech (NASDAQ: ALVO) tilkynnti í dag að fyrirtækið hafi keypt þróunarstarfsemi sænska líftæknifyrirtækisins Xbrane Biopharma AB (“Xbrane”). Með kaupunum eykur Alvotech afkastagetu sína í þróun nýrra líftæknilyfjahliðstæða, styrkir stöðu sína sem leiðandi afl á þessu sviði og haslar sér völl innan sænska líftæknigeirans. Alvotech tekur yfir aðstöðu og búnað Xbrane, við Karólínska sjúkrahúsið í Stokkhólmi og starfsfólk í þróunardeild fyrirtækisins. Með kaupunum eignast Alvotech jafnframt allt lyfjahugvit Xbrane tengt f...

 PRESS RELEASE

Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirm...

Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production REYKJAVIK, Iceland and STOCKHOLM, March 20, 2025 (GLOBE NEWSWIRE) --  Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the acquisition of Xbrane Biopharma AB’s (“Xbrane”) R&D operations and a biosimilar candidate (the “Acquisition”), further expanding Alvotech’s development capabilities, and establishing a footprint in the Swedish life...

 PRESS RELEASE

Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License A...

Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”) and Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted a 351(k) Biologic License Application (BLA) submission for AVT03, developed by ...

 PRESS RELEASE

Matvæla- og lyfjaeftirlit Bandaríkjanna (FDA) samþykkir að taka til af...

Matvæla- og lyfjaeftirlit Bandaríkjanna (FDA) samþykkir að taka til afgreiðslu umsókn um markaðsleyfi fyrir AVT03, fyrirhugaða hliðstæðu við Prolia og Xgeva Alvotech (NASDAQ: ALVO) og samstarfsaðili þess, alþjóðlega lyfjafyrirtækið Dr. Reddy‘s Laboratories Ltd. („Dr. Reddy‘s“) tilkynntu í dag að Matvæla- og lyfjaeftirlit Bandaríkjanna (FDA) hafi samþykkt að taka til afgreiðslu umsókn um markaðsleyfi fyrir AVT03, fyrirhugaða líftæknilyfjahliðstæðu við Prolia og Xgeva, sem bæði innihalda virka efnið denosumab. „Samþykki FDA á því að taka umsókn um markaðsleyfi fyrir denosumab-hliðstæðuna til...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch